Aquestive Therapeutics, Inc.

NASDAQ:AQST

Drug Manufacturers - Specialty & Generic

Healthcare
$3.78 +5.08%

+$0.23 today

Market cap
$475.10M
Beta
1.45
P/E (TTM)
-8.3
EPS (TTM)
-$0.56
52W Low $2.93High $7.55

Volume 1.80M

Average 1.51M

AQST Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Aquestive Therapeutics, Inc.NASDAQ: AQST

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $113K fell 18.7% year over year, ahead of the -19.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 13.1% from the prior quarter. Over 3 fiscal years it compounded at -38.8% a year.

Context

  • Depreciation & amortization amounted to 1.2% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -18.7% holds above the trailing-twelve-month pace of -19.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$113K-13.1% QoQ
Last fiscal yearDec 2025
$548K-23.7% YoY
LTMMar 2026
$522K-19.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.7%——
1 year-23.7%——
3-year CAGR-38.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
548K USD
Year-over-year change
-23.7%
4-year CAGR
-34.4%

Depreciation & Amortization vs competitors

How AQST compares with its peers on the latest reported figures

  • AQST's LTM Mar 2026 depreciation & amortization of $522K is the smallest of the 10 companies compared; the peer median is $12.47M.
  • Its year-over-year change of -19.7% is the 9th highest of 10, against a peer median of +17.1%.
  • Depreciation & amortization amounts to 1.0% of revenue for AQST, versus a peer median of 6.8%.
AQST Competitors Peer median
Depreciation & Amortization for AQST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$227.86M +19.7%+16.7%28.6%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$101.71M +26.1%+2.3%12.2%
ALKSAlkermes plcLTM Sep 2026$80.71M +167.6%-29.6%4.6%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$57.48M +44.0%+30.0%8.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.47M +3.0%-1.4%4.0%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$8.66M +9.7%—4.0%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$5.25M -11.5%-0.3%12.5%
DERMJourney Medical CorporationLTM Mar 2026$4.41M +17.1%+2.7%6.8%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$2.77M -57.2%+62.5%2.3%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$522K -19.7%-38.8%1.0%
Peer median (excluding AQST) $12.47M+17.1%+2.5%6.8%

Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.54M)(54.41M)(7.87M)(44.14M)(83.78M)
Depreciation & Amortization2.96M2.39M1.35M718K548K
Deferred Income Tax00000
Stock-Based Compensation6.82M4.38M2.69M7.1M7.62M
Change in Working Capital(1.73M)32.01M(5.34M)(9.96M)12.18M
Accounts Receivables(5.35M)7.35M(3.07M)1.09M(10.37M)
Inventory(1.58M)(1.74M)(989K)725K(126K)
Accounts Payables1.23M1.63M(1.02M)2.78M19.52M
Other Working Capital3.98M24.77M(259K)(14.56M)3.16M
Other Non-Cash Items29.51M5.85M2.8M10.52M11M
Operating Cash Flow(32.98M)(9.79M)(6.38M)(35.76M)(52.43M)
Capital Expenditures(913K)(2.52M)(995K)(159K)(562K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(913K)(2.52M)(995K)(159K)(562K)
Debt Repayment0(2.03M)(20.39M)(23K)(37K)
Common Stock Issued29.78M13.59M8.91M83.76M103.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities329K1K15.45M(142K)(810K)
Financing Cash Flow30.11M11.56M3.97M83.59M102.62M
Effect of Forex Changes00000
Net Change in Cash(3.78M)(751K)(3.4M)47.67M49.62M
Free Cash Flow(33.89M)(12.31M)(7.38M)(35.92M)(52.99M)

Aquestive Therapeutics, Inc.

NASDAQ:AQST

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.